SYRE Key Statistics, Chart & Performance
The current stock price of SYRE is 33.05 USD. In the past month the price increased by 13.18%. In the past year, price increased by 39.63%.
SYRE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.33 | 406.30B | ||
| AMGN | AMGEN INC | 15.27 | 179.83B | ||
| GILD | GILEAD SCIENCES INC | 15.34 | 155.92B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.67 | 117.47B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.41 | 82.37B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 785.67 | 52.94B | ||
| INSM | INSMED INC | N/A | 37.84B | ||
| NTRA | NATERA INC | N/A | 32.51B | ||
| BIIB | BIOGEN INC | 10.53 | 25.87B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.5 | 22.16B | ||
| INCY | INCYTE CORP | 15.64 | 19.72B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About SYRE
Company Profile
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. The company is headquartered in Waltham, Massachusetts and currently employs 95 full-time employees. The company went IPO on 2016-04-07. Its pipeline includes investigational extended half-life antibodies targeting a4b7, TL1A, and IL-23. Its pipeline programs include SPY003, SPY004, SPY130, SPY230, SPY002, SPY001, and SPY120. Its advanced product candidate, SPY001, is a fully human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4b7 integrin being developed for the treatment of IBD. Its co-lead program, SPY002, has nominated two fully human mAb candidates designed to bind to tumor necrosis factor-like ligand 1A (TL1A), both of which are in preclinical development for the treatment of IBD. SPY003 is a preclinical-stage program designed to bind to Interleukin 23 (IL-23) and incorporates half-life extending modifications.
Company Info
SPYRE THERAPEUTICS INC
221 Crescent Street, Suite 105
Waltham MASSACHUSETTS US
Employees: 65
Phone: 16176515940.0
SPYRE THERAPEUTICS INC / SYRE FAQ
What does SPYRE THERAPEUTICS INC do?
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. The company is headquartered in Waltham, Massachusetts and currently employs 95 full-time employees. The company went IPO on 2016-04-07. Its pipeline includes investigational extended half-life antibodies targeting a4b7, TL1A, and IL-23. Its pipeline programs include SPY003, SPY004, SPY130, SPY230, SPY002, SPY001, and SPY120. Its advanced product candidate, SPY001, is a fully human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4b7 integrin being developed for the treatment of IBD. Its co-lead program, SPY002, has nominated two fully human mAb candidates designed to bind to tumor necrosis factor-like ligand 1A (TL1A), both of which are in preclinical development for the treatment of IBD. SPY003 is a preclinical-stage program designed to bind to Interleukin 23 (IL-23) and incorporates half-life extending modifications.
What is the current price of SYRE stock?
The current stock price of SYRE is 33.05 USD. The price decreased by -0.54% in the last trading session.
What is the dividend status of SPYRE THERAPEUTICS INC?
SYRE does not pay a dividend.
How is the ChartMill rating for SPYRE THERAPEUTICS INC?
SYRE has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What sector and industry does SPYRE THERAPEUTICS INC belong to?
SPYRE THERAPEUTICS INC (SYRE) operates in the Health Care sector and the Biotechnology industry.
What is SPYRE THERAPEUTICS INC worth?
SPYRE THERAPEUTICS INC (SYRE) has a market capitalization of 2.56B USD. This makes SYRE a Mid Cap stock.
SYRE Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to SYRE. When comparing the yearly performance of all stocks, SYRE is one of the better performing stocks in the market, outperforming 95.41% of all stocks.
SYRE Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to SYRE. While SYRE has a great health rating, there are worries on its profitability.
SYRE Financial Highlights
Over the last trailing twelve months SYRE reported a non-GAAP Earnings per Share(EPS) of -2.33. The EPS increased by 68.81% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -34.19% | ||
| ROE | -40.17% | ||
| Debt/Equity | 0 |
SYRE Forecast & Estimates
19 analysts have analysed SYRE and the average price target is 53.13 USD. This implies a price increase of 60.76% is expected in the next year compared to the current price of 33.05.
For the next year, analysts expect an EPS growth of 48.4% and a revenue growth -100% for SYRE